![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
在复发性/耐药性扩散性大B细胞淋巴瘤中使用新型疗法的现实结果
Jennifer L Crombie1, Monika Jun2, Tongsheng Wang2
1Dana-Farber Cancer Institute, Boston, MA, USA.
Leukemia & lymphoma
|July 16, 2024
概括
针对复发性/耐药性扩散性大B细胞淋巴瘤 (DLBCL) 的新型疗法在现实世界中表现出不同的有效性. 化学抗原受体T细胞 (CAR T) 疗法提供了更长的生存期,但在CAR T复发后的结果很差,需要新的治疗选择.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 临床研究 临床研究
背景情况:
- 扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的非霍奇金淋巴瘤.
- 复发性/耐药性 (R/R) DLBCL 存在重大治疗挑战.
- 新疗法正在出现,但现实世界的数据至关重要.
研究的目的:
- 评估R/R DLBCL新型疗法的现实世界结果.
- 为了比较化学抗原受体T细胞 (CAR T) 疗法与基于波拉图祖马布和塔法西他姆的疗法.
- 为了确定R/R DLBCL治疗的未满足需求.
主要方法:
- 对美国R/R DLBCL患者 (2010-2021) 的非识别COTA数据 (2010-2021) 的分析.
- 包括接受CAR T,基于波拉图祖马布或基于tafasitamab的疗法的患者.
- 对人口统计,临床特征和生存结果的评估.
主要成果:
- 分析了175名R/R DLBCL患者:73名 (CAR T),69名 (波拉图祖马布),27名 (塔法西他马布).
- 第二线或后期治疗 (2L+) 的平均整体存活时间为26.5个月 (CAR T),7.8个月 (波拉图祖马布) 和6.3个月 (塔法西他马布).
- 在CAR T后复发的患者中,结局不佳,这表明波拉图祖马布和塔法西他马布在这种情况下的疗效不足最佳.
结论:
- 在2L+R/R DLBCL中,CAR T疗法表现出较高的平均整体存活率,与以波拉图祖马布和塔法西他马布为基础的疗法相比.
- 在2L+ R/R DLBCL中,以波拉图祖马布和塔法西他马布为基础的治疗方案的现实结果是不理想的.
- 对于R/R DLBCL患者,特别是在CAR T衰竭后,急需提供额外和改进的治疗选择.
更多相关视频
06:08Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
Published on: February 10, 2023
1.3K
06:51Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
15.0K
相关概念视频
01:27Tumor Immunotherapy
509
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
509
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K